TG Therapeutics will hold a conference call on February 26, 2026, to discuss Q4 and 2025 results.
Quiver AI Summary
TG Therapeutics, Inc. announced a conference call scheduled for February 26, 2026, at 8:30 AM ET to discuss its fourth quarter and full year financial results for 2025 and to provide a business outlook for 2026. The call will be hosted by CEO Michael S. Weiss, and participants can join by calling specific numbers or by listening to a live webcast available on the company's website. A press release detailing the financial results will be issued prior to the call, and a recording will be available for replay afterward. TG Therapeutics is a biotechnology company focused on innovative treatments for B-cell diseases and has FDA approval for its drug BRIUMVI® for specific types of multiple sclerosis.
Potential Positives
- TG Therapeutics is set to provide insights into its financial performance for Q4 and full year 2025, indicating transparency and engagement with investors.
- The company will provide a business outlook for 2026 during the conference call, which can signal growth potential and strategic direction.
- TG Therapeutics has received FDA approval for BRIUMVI®, enhancing its position in the market for treating relapsing forms of multiple sclerosis and potentially increasing revenue.
- The press release includes multiple accessible formats for investors to engage with the company's performance, including a live webcast and an audio recording of the call.
Potential Negatives
- There is no financial performance announced in advance of the earnings call, which may indicate disappointing results that the company is cautious about revealing.
- The timing of the earnings call shortly after the end of a fiscal quarter could suggest ongoing financial instability or uncertainty in meeting market expectations.
- Potential lack of engagement or interest among investors due to the company's need to provide a business outlook during the call, which may signal a lack of confidence in their future performance.
FAQ
What is the date and time of the TG Therapeutics conference call?
The TG Therapeutics conference call is scheduled for Thursday, February 26, 2026, at 8:30 AM ET.
How can I participate in the TG Therapeutics conference call?
To participate in the call, dial 1-877-407-8029 (U.S.) or 1-201-689-8029 (outside the U.S.).
Where can I find the live webcast for the earnings call?
The live webcast will be available on the Events page in the Investors & Media section of TG Therapeutics' website.
How long will the audio recording of the conference call be available?
The audio recording will be available for replay for 30 days after the conference call on the website.
What recent approval has TG Therapeutics received from the FDA?
TG Therapeutics has received FDA approval for BRIUMVI® to treat adult patients with relapsing forms of multiple sclerosis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$TGTX Insider Trading Activity
$TGTX insiders have traded $TGTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:
- SAGAR LONIAL sold 20,852 shares for an estimated $672,268
- YANN ECHELARD sold 5,000 shares for an estimated $162,850
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$TGTX Revenue
$TGTX had revenues of $161.7M in Q3 2025. This is an increase of 92.79% from the same period in the prior year.
You can track TGTX financials on Quiver Quantitative's TGTX stock page.
$TGTX Hedge Fund Activity
We have seen 178 institutional investors add shares of $TGTX stock to their portfolio, and 213 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CONGRESS ASSET MANAGEMENT CO added 1,922,410 shares (+inf%) to their portfolio in Q4 2025, for an estimated $57,307,042
- CLEARBRIDGE INVESTMENTS, LLC removed 1,196,442 shares (-25.8%) from their portfolio in Q4 2025, for an estimated $35,665,936
- DRIEHAUS CAPITAL MANAGEMENT LLC removed 807,833 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $29,182,967
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 741,518 shares (-75.6%) from their portfolio in Q4 2025, for an estimated $22,104,651
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 705,419 shares (-18.3%) from their portfolio in Q4 2025, for an estimated $21,028,540
- BNP PARIBAS FINANCIAL MARKETS added 612,189 shares (+856.6%) to their portfolio in Q4 2025, for an estimated $18,249,354
- JUMP FINANCIAL, LLC removed 595,356 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $17,747,562
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$TGTX Analyst Ratings
Wall Street analysts have issued reports on $TGTX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 10/06/2025
- B. Riley Securities issued a "Buy" rating on 09/17/2025
To track analyst ratings and price targets for $TGTX, check out Quiver Quantitative's $TGTX forecast page.
$TGTX Price Targets
Multiple analysts have issued price targets for $TGTX recently. We have seen 5 analysts offer price targets for $TGTX in the last 6 months, with a median target of $49.0.
Here are some recent targets:
- Brian Cheng from JP Morgan set a target price of $46.0 on 02/02/2026
- Corinne Johnson from Goldman Sachs set a target price of $39.0 on 01/15/2026
- Emily Bodnar from HC Wainwright & Co. set a target price of $60.0 on 10/06/2025
- Mayank Mamtani from B. Riley Securities set a target price of $55.0 on 09/17/2025
Full Release
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Thursday, February 26, 2026, at 8:30 AM ET to discuss results for the fourth quarter and full year 2025 and to provide a business outlook for 2026. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com . An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com , for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit
www.tgtherapeutics.com
, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
| CONTACT: | |
| Investor Relations | |
| Email: [email protected] | |
| Telephone: 1.877.575.TGTX (8489), Option 4 | |
| Media Relations: | |
| Email: [email protected] | |
| Telephone: 1.877.575.TGTX (8489), Option 6 | |
